Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas
Authors
Keywords
BRAF V600E, PLX4720, PLX4032, vemurafenib, Radiosensitization
Journal
INVESTIGATIONAL NEW DRUGS
Volume 31, Issue 5, Pages 1136-1141
Publisher
Springer Nature
Online
2013-01-25
DOI
10.1007/s10637-013-9928-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets
- (2012) Keith T. Flaherty CLINICAL & EXPERIMENTAL METASTASIS
- Survival Advantage With Radiation Combined With a Selective BRAFV600E Inhibitor in an Orthotopic, Intracranial Model of BRAFV600E-mutated High-grade Gliomas
- (2012) T. Dasgupta et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas
- (2012) C. Horbinski et al. NEURO-ONCOLOGY
- The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
- (2012) Gholamreza Safaee Ardekani et al. PLoS One
- Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms
- (2011) Sabine Mueller et al. CANCER LETTERS
- Targeted Therapy for BRAFV600E Malignant Astrocytoma
- (2011) T. P. Nicolaides et al. CLINICAL CANCER RESEARCH
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032
- (2011) Maria J. Sambade et al. RADIOTHERAPY AND ONCOLOGY
- The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204)
- (2010) Joanna Xing et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas
- (2010) J. D. Schiffman et al. CANCER RESEARCH
- B-Raf Inhibitor PLX4720 Enhances the Activity of Radiation and Temozolomide in a Human Glioblastoma Cell Line
- (2010) T. Dasgupta et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1
- (2009) J. C. Ricarte-Filho et al. CANCER RESEARCH
- Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors inBRAFMutant Thyroid Carcinoma Cells
- (2009) Paolo Salerno et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Prognostic utility of BRAF mutation in papillary thyroid cancer
- (2009) Mingzhao Xing MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
- (2008) Robert C Smallridge et al. ENDOCRINE-RELATED CANCER
- Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification
- (2008) Rebecca E. Schweppe et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells
- (2008) E. Sala et al. MOLECULAR CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started